In addition, both mithramycin A and its analog (mithralog) EC-8042 effectively suppress SETDB1 expression in melanoma cells and enhance the efficacy of mitogen-activated protein kinase-inhibitor-based therapies for melanoma [38]. The gene discussed is SETDB1; the disease is melanoma.